A Small-Cap Buy That’s Not So Spooky

This October has been one “spooky” month for the market. The underlying fundamentals of the market remain positive.

Insuline: Significant Upside, Alternative Diabetes Play With A Population Based Cost-Reduction Platform In Diabetes

Big Picture Thesis: Since Afrezza’s approval MannKind’s (NASDAQ:MNKD) shares have declined more than 50% as enthusiasm for their partnership with Sanofi-Aventis (NYSE:SNY) has …

QLT Inc. Left By Auxilium: Favorable Risk/Reward In Uncertain Market

Endo Health (NASDAQ:ENDP) and Auxilium Pharmaceuticals (NASDAQ:AUXL) finally came to terms in ongoing buyout negotiations, with ENDP handing over $2.6 billion ($33.

Achillion: Positioned To Deliver The Last Clinical Stage Nuc To The Highest Bidder

Investment Thesis We expect volatility in the share prices of HCV focused companies leading into this year’s AASLD meeting from November 7th to …

A Bizarre Pharma Love Triangle

Back on July 3rd of this year, I wrote about a good find in pharma called Salix Pharmaceuticals (NASDAQ:SLXP). Salix Pharmaceuticals is a …

Infrequently Asked Questions: Sequenom

In what I hope will become the first in a series of Infrequently Asked Questions, I was able to chat with Sequenom (NASDAQ:SQNM) …

Identiv’s Q2 Earnings Show Strong Growth – Acquisition Likely At Some Point

Yesterday after the bell, Identiv Inc (NASDAQ:INVE) reported its Q2, 2014 earnings. As I have remarked previously, the company is under an entirely …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts